VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Vaxcyte
PCVX
$4.29B
| $96K | 0.06% |
1,528
-355
| -19% | -$22.3K |
|
377
89bio
ETNB
$1.32B
| $95.9K | 0.06% |
8,588
+3,969
| +86% | +$44.3K |
|
|
BLTE
378
Belite Bio
BLTE
$2.16B
| $95.9K | 0.06% |
+2,096
| New | +$95.9K |
|
379
Recursion Pharmaceuticals
RXRX
$2.01B
| $95.8K | 0.06% |
9,715
-317
| -3% | -$3.13K |
|
380
Biomea Fusion
BMEA
$114M
| $95.7K | 0.06% |
6,589
+4,046
| +159% | +$58.7K |
|
381
MacroGenics
MGNX
$126M
| $95.7K | 0.06% |
+9,944
| New | +$95.7K |
|
382
Dynavax Technologies
DVAX
$1.18B
| $95.4K | 0.06% |
6,823
-1,008
| -13% | -$14.1K |
|
|
SLRN
383
DELISTED
ACELYRIN
SLRN
| $94.9K | 0.06% |
+12,717
| New | +$94.9K |
|
384
Day One Biopharmaceuticals
DAWN
$773M
| $94.8K | 0.06% |
6,492
-847
| -12% | -$12.4K |
|
385
Sana Biotechnology
SANA
$752M
| $94.7K | 0.06% |
+23,203
| New | +$94.7K |
|
386
Phathom Pharmaceuticals
PHAT
$875M
| $94.7K | 0.06% |
10,367
+2,623
| +34% | +$23.9K |
|
387
Crinetics Pharmaceuticals
CRNX
$3.35B
| $94.4K | 0.06% |
2,654
-2,195
| -45% | -$78.1K |
|
|
ITOS
388
DELISTED
iTeos Therapeutics
ITOS
| $94.1K | 0.06% |
8,596
+1,530
| +22% | +$16.8K |
|
389
Scholar Rock
SRRK
$3.02B
| $93.8K | 0.06% |
+4,988
| New | +$93.8K |
|
390
Zentalis Pharmaceuticals
ZNTL
$126M
| $93.8K | 0.06% |
6,189
+2,177
| +54% | +$33K |
|
|
ALPN
391
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $93.5K | 0.06% |
+4,904
| New | +$93.5K |
|
392
Oric Pharmaceuticals
ORIC
$1.06B
| $92.8K | 0.06% |
+10,085
| New | +$92.8K |
|
393
Vir Biotechnology
VIR
$732M
| $92.8K | 0.06% |
9,221
+5,419
| +143% | +$54.5K |
|
394
Terns Pharmaceuticals
TERN
$632M
| $92.7K | 0.06% |
14,287
+5,883
| +70% | +$38.2K |
|
395
Xencor
XNCR
$610M
| $92.6K | 0.06% |
4,363
+641
| +17% | +$13.6K |
|
396
Kymera Therapeutics
KYMR
$3.11B
| $92.6K | 0.06% |
3,638
-199
| -5% | -$5.07K |
|
397
Alector
ALEC
$305M
| $92.4K | 0.06% |
11,573
-1,258
| -10% | -$10K |
|
398
Madrigal Pharmaceuticals
MDGL
$9.65B
| $91.9K | 0.06% |
397
+9
| +2% | +$2.08K |
|
399
Disc Medicine
IRON
$2.11B
| $91.8K | 0.06% |
1,589
-425
| -21% | -$24.5K |
|
400
Immunovant
IMVT
$2.99B
| $91.6K | 0.06% |
2,174
-2,473
| -53% | -$104K |
|